GlassScriptPhysician profile
Sajeda Nusrat
NPI 1912993924
$1,461.71
in general payments reported to CMS, 2019-2025
18 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.00 · 2021: $12.14 · 2022: $244 · 2023: $345 · 2024: $526 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.48 | 2022-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $175.49 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $165.67 | 2022-2025 | |
| Glaxosmithkline, LLC. | $164.20 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $130.61 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $104.13 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $64.43 | 2023-2024 | Rexulti |
| Medtronic, INC. | $63.50 | 2024 | Activos 10 Bone Cement |
| Bayer Healthcare Pharmaceuticals INC. | $60.51 | 2022-2024 | |
| Amgen INC. | $58.00 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $45.39 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $33.48 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $27.89 | 2024 | Eliquis |
| Boston Scientific Corporation | $22.90 | 2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $18.96 | 2024 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2023 | Xifaxan |
| Abbott Laboratories | $15.02 | 2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $13.60 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajeda Nusrat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.